Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obseva SA    OBSV   CH0346177709

OBSEVA SA (OBSV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
14.97(c) 14.02(c) 15(c) 14.55(c) 17.87(c) Last
159 367 49 094 473 272 33 474 956 866 Volume
+2.39% -6.35% +6.99% -3.00% +22.82% Change
More quotes
Financials (USD)
Sales 2018 0,01 M
EBIT 2018 -84,5 M
Net income 2018 -84,1 M
Finance 2018 19,3 M
Yield 2018 -
Sales 2019 0,01 M
EBIT 2019 -98,9 M
Net income 2019 -98,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 46 103x
Capi. / Sales2019 41 558x
Capitalization 540 M
More Financials
Company
ObsEva SA engages in the development of therapeutic treatments for woman's reproductive health and pregnancy.It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth.The company was founded by Ernest Loumaye and André Chollet in November 2012 and is... 
More about the company
Surperformance© ratings of Obseva SA
Trading Rating : Investor Rating :
More Ratings
Latest news on OBSEVA SA
06/15ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS ..
GL
02/28OBSEVA SA : Wired News – ObsEva Released Positive Top-line Results from IMPLANT2..
AC
02/23ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 p..
GL
2017ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm La..
GL
2017ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with..
GL
2017ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Ca..
GL
2017OBSEVA : Starts Phase 3 Clinical Program for Nolasiban in ART
PU
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/16ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS .. 
06/16Want the latest analyst ratings on $OBSV $GRFS $NVTR $CNBKA $SPXC? Get Them D.. 
06/16$OBSV: ObsEva to announce topline results of the EDELWEISS Phase 2b clinical .. 
06/15Obseva $OBSV Given a $28.00 Price Target at HC Wainwright  
06/13Obseva $OBSV PT Set at $28.00 by HC Wainwright  
More tweets
Qtime:52
News from SeekingAlpha
06/15Key events next week - healthcare 
06/12Premarket analyst action - healthcare 
06/01ObsEva to seek SIX share listing 
05/16ObsEva' (OBSV) CEO Ernest Loumaye Q1 2018 Results - Earnings Call Transcript 
05/16ObsEva misses by $0.07 
Chart OBSEVA SA
Duration : Period :
Obseva SA Technical Analysis Chart | OBSV | CH0346177709 | 4-Traders
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 25,3 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Ernest Loumaye Chief Executive Officer & Director
Frank A. G. M. Verwiel Chairman
Timothy M. Adams Chief Financial Officer
Jean-Pierre Gotteland Chief Scientific Officer
Elke Bestel Chief Medical Officer & Head-Pharmacovigilance
Sector and Competitors
1st jan.Capitalization (M$)
OBSEVA SA49.08%540
GILEAD SCIENCES-0.68%91 317
VERTEX PHARMACEUTICALS3.42%39 504
REGENERON PHARMACEUTICALS-16.04%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
GENMAB-6.67%9 197